Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer’s Disease?

2020 ◽  
Vol 74 (2) ◽  
pp. 411-419 ◽  
Author(s):  
Kelly Ceyzériat ◽  
Benjamin B. Tournier ◽  
Philippe Millet ◽  
Giovanni B. Frisoni ◽  
Valentina Garibotto ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Radiation Therapy ◽  
Treatment Strategy ◽  
Low Dose ◽  
Low Dose Radiation ◽  
New Treatment ◽  
Dose Radiation

Combining Low-Dose Radiation Therapy and Magnetic Resonance Guided Focused Ultrasound to Reduce Amyloid-β Deposition in Alzheimer’s Disease

2021 ◽  
pp. 1-4
Author(s):  
Paolo Farace ◽  
Stefano Tamburin
Keyword(s):  
Alzheimer’S Disease ◽  
Clinical Trials ◽  
Radiation Therapy ◽  
White Matter ◽  
Magnetic Resonance ◽  
Low Dose ◽  
Focused Ultrasound ◽  
Amyloid Β ◽  
Low Dose Radiation ◽  
Dose Radiation

Amyloid-β deposition is one of the neuropathological hallmarks of Alzheimer’s disease (AD), but pharmacological strategies toward its reduction are poorly effective. Preclinical studies indicate that low-dose radiation therapy (LD-RT) may reduce brain amyloid-β. Animal models and proof-of-concept preliminary data in humans have shown that magnetic resonance guided focused ultrasound (MRgFUS) can reversibly open the blood-brain-barrier and facilitate the delivery of targeted therapeutics to the hippocampus, to reduce amyloid-β and promote neurogenesis in AD. Ongoing clinical trials on AD are exploring whole-brain LD-RT, which may damage radio-sensitive structures, i.e., hippocampus and white matter, thus contributing to reduced neurogenesis and radiation-induced cognitive decline. However, selective irradiation of cortical amyloid-β plaques through advanced LD-RT techniques might spare the hippocampus and white matter. We propose combined use of advanced LD-RT and targeted drug delivery through MRgFUS for future clinical trials to reduce amyloid-β deposition in AD since its preclinical stages.

The Effect of Low Dose Radiation on Alzheimer's Disease-Induced TG Mice

2018 ◽  
Vol 102 (3) ◽  
pp. e210-e211 ◽  
Author(s):  
S.Y. Choi ◽  
N.H. Kwon ◽  
S.T. Kim ◽  
D.W. Kim ◽  
M.J. Chung ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Low Dose ◽  
Low Dose Radiation ◽  
Dose Radiation

Plasma cell infiltration of the upper aerodigestive tract treated with radiation therapy

2001 ◽  
Vol 115 (11) ◽  
pp. 928-930 ◽  
Author(s):  
Gerald Fogarty ◽  
Hugh Turner ◽  
June Corry
Keyword(s):  
Radiation Therapy ◽  
Plasma Cell ◽  
Low Dose ◽  
Symptomatic Improvement ◽  
Upper Aerodigestive Tract ◽  
Low Dose Radiation ◽  
Base Of Tongue ◽  
First Case ◽  
Mucosal Lining ◽  
Dose Radiation

A case of chronic, fluctuating plasma cell gingivostomatitis that progressed despite chemotherapy and surgery is reported. This is the first case reported of treatment with radiation therapy, and one of the few cases reported where the infiltrate has reached the larynx. After receiving low dose radiation therapy, via a conformal technique encompassing the respiratory mucosal lining from the base of tongue to carina, there has been symptomatic improvement.

scholarly journals Low-Dose Radiation Therapy for COVID-19 Pneumonia: review

2020 ◽  
pp. 30-34
Author(s):  
N. Kolotilov
Keyword(s):  
Radiation Therapy ◽  
Low Dose ◽  
Ore Deposits ◽  
Molecular Targeting ◽  
Positive Experience ◽  
Low Dose Radiation ◽  
Coronavirus Infection ◽  
Positive Results ◽  
Dose Radiation ◽  
Radiolabeled Antibodies

The use of low-dose radiation therapy (LDRT) in patients with pneumonia from 1905 to 1943 provided positive results in 83.08 % of cases. Interest in LDRT is supported by researchers of radiation hormesis in the 21st century. Attention is drawn to the dynamics of coronavirus infection in the regions of Ukraine and the Kirovograd region with a minimum incidence. It is known that 95 % of uranium ore deposits in Ukraine are concentrated in the Kirovograd region. The positive experience of LDRT in Iran, India, USA, Spain for the treatment of patients with COVID-19 is described. LDRT (<100 cGy) is known to be anti-inflammatory, and therefore pulmonary LDRT has the potential to reduce the severity of pneumonia and reduce mortality. LDRT deserves a clinical study. A new direction in radiation therapy – Auger therapy based on radiolabeled antibodies – is planned to be used as a molecular targeting radiotherapy agent directly to the SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document